# Incyte (INCY) — News

INCY · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/incy/news

## Recent headlines

- [INEOS Energy $700M 5NC2 notes 9.25% area](https://www.ainvest.com/news/ineos-energy-700m-5nc2-notes-9-25-area-2610) — AInvest Wire, Oct 14, 2026
  INEOS Holdings Limited has announced the launch of a new offering of senior secured notes, reflecting the company’s ongoing efforts to manage its debt structure and optimize financial flexibility. The offering, led by its wholly owned subsidiary INEOS Finance plc, involves euro-denominated senior…
- [Select Water Solutions $800M 8NC3 notes 7.5% to 7.75% range](https://www.ainvest.com/news/select-water-solutions-800m-8nc3-notes-7-5-7-75-range-2610) — AInvest Wire, Oct 14, 2026
- [Incyte: Truist Securities raises target price to $115 from $105](https://www.ainvest.com/news/incyte-truist-securities-raises-target-price-115-105-2610) — AInvest Wire, Oct 14, 2026
  Truist Securities has raised its price target for Incyte Corporation (INCY) to $115 from $105, reflecting a positive outlook on the biopharmaceutical company’s stock performance and strategic positioning. The updated target suggests increased confidence in Incyte’s ability to deliver value to…
- [Incyte sharefollow Syndax lower postmarket, down 3.9%](https://www.ainvest.com/news/incyte-sharefollow-syndax-postmarket-3-9-2610) — AInvest Wire, Oct 12, 2026
  Incyte Corp. (INCY) shares declined postmarket on October 12, 2026, falling 3.9% following news related to Syndax Pharmaceuticals. The drop came amid market reactions to updated clinical or partnership developments involving Syndax, which has a collaboration with Incyte in the oncology space. While…
- [Mirum Pharma: Study met primary endpoint: MIRM US](https://www.ainvest.com/news/mirum-pharma-study-met-primary-endpoint-mirm-2610) — AInvest Wire, Oct 12, 2026
  Mirum Pharmaceuticals (NASDAQ: MIRM) announced that the primary endpoint was met in its Phase 3 AZURE-1 study of Brelovitug, a fully human monoclonal antibody targeting the hepatitis B surface antigen for the treatment of chronic hepatitis delta virus (HDV) infection. The achievement marks a…

## Similar Stocks

- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).